DOCSLIB.ORG

PAX Labs Announces Formation of Health Advisory Board

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PAX Labs Announces Formation of Health Advisory Board This site uses cookies. By continuing to browse this Business Wire site (and/or any other Business Wire website), you accept the use of cookies. Learn more (/portal/site/home/privacy/) I agree PAX Labs Announces Formation of Health Advisory Board Additional Expertise Amid Growing Concerns about the Safety of Illicit Cannabis Products September 25, 2019 09:00 AM Eastern Daylight Time SAN FRANCISCO--(BUSINESS WIRE)--PAX Labs, Inc., a leading consumer technology brand in cannabis, today announced the formation of a health advisory board. Composed of highly respected experts across immunology, cannabis research and patient safety, this board underscores PAX’s commitment to consumer health. The board will meet quarterly and advise on key areas including vaporization safety, mental health and medical applications for PAX products. “Amid growing concern about the risks—and prevalence—of illicit cannabis, our top priority at PAX remains consumer safety,” said PAX President and CEO Lisa Sergi. “The formation of this board has been in the works for some time. It’s an obvious next step for PAX as we blend our industry-leading innovation with continuous research in cannabis and vapor technology.” “Our customers expect us to make wise choices regarding their health and safety, and we take that responsibility very seriously,” said Conrad Legendy, Director of Applied Research at PAX. “We look forward to drawing on our health advisory board’s expertise and thought leadership as we continue to develop category-defining products.” “I’ve pursued my passion for cannabis product safety for over a decade and look forward to continuing that work through this role with PAX,” said Dr. Jahan Marcu, Co- founder of the International Research Center on Cannabis and Health. “The formation of this board speaks volumes to PAX’s commitment to prioritizing the best interests of consumers and patients.” Background on Health Advisory Board Members Dr. Anne Maitland, M.D., Ph.D. is a thought leader on immune-mediated disorders and the emerging field of Mast Cell disorders. She currently serves as an Assistant Professor at Mount Sinai Hospital in New York and a Medical Director of Comprehensive Allergy & Asthma Care in Westchester. She is on advisory boards for The Ehlers Danlos Society, The Mastocytosis Society, Dysautonomia International, and the Chiari Syringomelia Foundation. Dr. Arno Hazekamp, Ph.D. is an acclaimed cannabis researcher and leader in vaporization science. He has been involved in the Dutch medicinal cannabis program since its inception, specializing in quality control, product development and clinical trial design, and is the former Head of Research and Education at Bedrocan BV—the Netherlands’ official medicinal cannabis grower. He is an active lecturer and advocate, and creator of the Medicinal Cannabis Masterclass. Dr. Douglas Melancon, M.D. is Co-research Director and oversees healthcare investments at Advent Capital Management. Dr. Melancon has deep expertise in analyzing and distilling complex medical and pharmaceutical research, and has a strong understanding of the FDA and navigating the complex regulatory environment. He previously served as a Portfolio Manager at Merlin Biomed and a Biotechnology Analyst at Morgan Stanley and Merrill Lynch. Dr. Jahan Marcu, Ph.D. has over 15 years of experience in cannabis research, policy, and operations. He is the Chief Science Officer and Co-founder of the International Research Center on Cannabis and Mental Health and was previously the Chief Science Officer at Americans for Safe Access. He serves on multiple advisory committees and is among a select group of professionals globally with a Ph.D. focused on the endocannabinoid system. About PAX Labs PAX is a leader in the design and development of premium app-controlled vaporization technologies and devices. Headquartered in San Francisco, PAX has revolutionized the consumer experience through innovation and product design, and is committed to taking the guesswork out of cannabis with products that offer quality, transparency, and predictability. PAX has sold more than 500,000 Era devices for oil concentrates and over one million devices in the flower vaporizer category. PAX is committed to its mission: establishing cannabis as a force for good. pax.com PAX Labs does not manufacture, produce or sell cannabis. Contacts PAX Labs Dianne Gleason [email protected].
Load more

Recommended publications
  • Surveillance of U.S. Corporate Filings Provides a Proactive Approach to Inform Tobacco Regulatory Research Strategy
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 25 January 2021 doi:10.20944/preprints202101.0472.v1 Article Surveillance of U.S. corporate filings provides a proactive approach to inform tobacco regulatory research strategy S. Emma Sarles 1, Edward C. Hensel 2* and Risa J. Robinson 3 1 PhD in Engineering Student, Rochester Institute of Technology, Rochester NY, USA; [email protected], https://orcid.org/0000-0003-4890-1820 2 Department of Mechanical Engineering, Rochester Institute of Technology, Rochester NY, USA; [email protected], https://orcid.org/0000-0002-2682-0766 3 Department of Mechanical Engineering, Rochester Institute of Technology, Rochester NY, USA; [email protected], https://orcid.org/0000-0001-8488-5448 * Correspondence: [email protected] Abstract: The popularity of electronic cigarettes in the United States and around the world has led to a startling rise in youth nicotine use. The Juul e-cigarette was introduced in the U.S. market in 2015 and had captured approximately 13% of the U.S. market by 2017. Unlike many other contemporary electronic cigarette companies, the founders behind the Juul® e-cigarette approached their product launch like a traditional high-tech start-up company, not like a tobacco company. This article presents a case study of Juul’s corporate and product development history in the context of US regulatory actions. The objective of this article is to demonstrate the value of government- curated archives as leading indicators which can (a) provide insight into emergent technologies and (b) inform emergent regulatory science research questions. A variety of sources were used to gather data about the Juul e-cigarette and the corporations that surround it.
    [Show full text]
  • Juul and Other High Nicotine E-Cigarettes Are Addicting a New Generation of Youth
    JUUL AND OTHER HIGH NICOTINE E-CIGARETTES ARE ADDICTING A NEW GENERATION OF YOUTH Launched in 2015, JUUL quickly disrupted the e-cigarette marketplace, popularizing e-cigarette devices that are sleek, discreet and have sweet flavors and a powerful nicotine hit. Nicotine is highly addictive, can negatively impact the development of the adolescent brain, and can harm the cardiovascular system.1 Youth e-cigarette use in the United States has skyrocketed to what the U.S. Surgeon General and the FDA have called “epidemic” levels, with 3.6 million middle and high school students using e- cigarettes. 2 Former FDA Commissioner Scott Gottlieb has stated, “There’s no question the Juul product drove a lot of the youth use.”3 The Surgeon General has called for “aggressive steps to protect our children from these highly potent products that risk exposing a new generation of young people to nicotine.”4 Use of Nicotine Salts Makes it Easier for New Users to Try E-Cigarettes Just like the tobacco industry has used additives and design changes to make cigarettes more addictive and appealing to new users (particularly youth),5 JUUL pioneered a new e-liquid formulation that delivers nicotine more effectively and with less irritation than earlier e-cigarette models. According to the company, the nicotine in JUUL is made from “nicotine salts found in leaf tobacco, rather than free-base nicotine,” in order to “accommodate cigarette-like strength nicotine levels.”6 JUUL’s original patent stated that, “certain nicotine salt formulations provide satisfaction in an individual superior to that of free base nicotine, and more comparable to the satisfaction in an individual smoking a traditional cigarette.
    [Show full text]
  • Emerging Issues in Tobacco Control: the Rise of Electronic Products and Implications for Policy, Planning, and Practice
    Emerging Issues in Tobacco Control: The Rise of Electronic Products and Implications for Policy, Planning, and Practice B R I A N A. KING, PHD, MPH DEPUTY DIRECTOR FOR RESEARCH TRANSLATION OFFICE ON SMOKING AND HEALTH State of Alaska Tobacco Prevention and Control Grantee Training Meeting ● November 14, 2018 1 What Are They? Why Are They 2 Popular? Who’s Using 3 Them? 4 Are They Safe? What Can We 5 Do About it? 1 What Are They? Why Are They 2 Popular? Who’s Using 3 Them? 4 Are They Safe? What Can We 5 Do About it? The Good News: Cigarette Smoking Is Down 40 35 30 25 smoking prevalence smoking 20 15 Cigarette Cigarette 10 5 0 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Adults 18+ High School Students Source: Adult cigarette smoking prevalence data are from the National Health Interview Survey (NHIS). High school cigarette smoking prevalence data are from the National Youth Risk Behavior Survey. The Bad News: The Landscape Is Evolving Cigars, Cigarillos Cigarettes Little Cigars Smokeless Pipes Tobacco Snus Hookah Bidis Dissolvables Kreteks E-cigarettes Heated Tobacco Products E-cigarettes: A Rapidly Diversifying Class The E-cigarette Landscape is Volatile Source: King, BA, Gammon DG, Marynak KL, Rogers T. Electronic Cigarette Sales in the United States, 2013-2017. JAMA October 2018;Volume 320:Number 13. The Rise of JUUL What Are “Heat Not Burn” Products? Contain Tobacco Throat Hit Similar to Cigarettes Pending FDA Pre-Market Approval A scientific advisory committee met to discuss the MRTP application in January 2018.
    [Show full text]
  • Heated Tobacco Products (Htps) Information Sheet May 2018 WHO/NMH/PND/17.6
    HEATED TOBACCO PRODUCTS (HTPS) INFORMATION SHEET MAY 2018 WHO/NMH/PND/17.6 What is a heated tobacco product? Heated tobacco products are tobacco products that produce aerosols containing nicotine and other chemicals, which are inhaled by users, through the mouth. They contain the highly addictive substance nicotine (contained in the tobacco), which makes HTPs addictive. They also contain non-tobacco additives, and are often flavoured. HTPs mimic the behaviour of smoking conventional cigarettes, and some make use of specifically designed cigarettes to contain the tobacco for heating. What are some examples of HTPs? Where are HTPs marketed? There are a number of these tobacco products HTPs are marketed or planned to be marketed in available on several markets. Examples include close to forty countries as of September 2017*, iQOS from Philip Morris International, Ploom and based on the current trend, it is likely that TECH from Japan Tobacco International, Glo these tobacco products will be introduced in from British American Tobacco, and PAX from more countries. PAX Labs. Are HTPs electronic-cigarettes? How do HTPs work? No, HTPs are not e-cigarettes. HTPs heat tobacco In order to produce the nicotine-infused vapor, to generate nicotine. E-cigarettes heat e-liquid, HTPs heat tobacco up to 350°C (lower than 600°C which may or may not contain nicotine and in as in conventional cigarettes) using battery- most cases do not contain tobacco. powered heating-systems. The heating-system enclosed in a device, can be an external heat source to aerosolize nicotine from specially designed cigarettes (e.g. iQOS and Glo), or a heated sealed chamber to aerosolize nicotine directly from tobacco leaf (ex.
    [Show full text]
  • Colgate V. JUUL Labs, Inc.: Addressing the Preemptive Scope of the Tobacco Control Act for Electronic Nicotine Delivery Systems
    Journal of Business & Technology Law Volume 15 Issue 1 Article 8 Colgate v. JUUL Labs, Inc.: Addressing the Preemptive Scope of the Tobacco Control Act for Electronic Nicotine Delivery Systems Daniel S. Hausman Follow this and additional works at: https://digitalcommons.law.umaryland.edu/jbtl Recommended Citation Daniel S. Hausman, Colgate v. JUUL Labs, Inc.: Addressing the Preemptive Scope of the Tobacco Control Act for Electronic Nicotine Delivery Systems, 15 J. Bus. & Tech. L. 215 (2019) Available at: https://digitalcommons.law.umaryland.edu/jbtl/vol15/iss1/8 This Notes & Comments is brought to you for free and open access by the Academic Journals at DigitalCommons@UM Carey Law. It has been accepted for inclusion in Journal of Business & Technology Law by an authorized editor of DigitalCommons@UM Carey Law. For more information, please contact [email protected]. Colgate v. JUUL Labs, Inc.: Addressing the Preemptive Scope of the Tobacco Control Act for Electronic Nicotine Delivery Systems DANIEL S. HAUSMAN*© ABSTRACT The promise offered by e-cigarette manufactures like JUUL Labs, Inc. of a healthier alternative to conventional combustible tobacco products has been eradicated as reports of skyrocketing teenage nicotine addiction and serious health concerns from the use of e-cigarettes continue to emerge. Ever since the Surgeon General declared tobacco a health risk in 1964, Congress and the judiciary have dealt with tobacco manufacturers who falsely advertised their product as safer to assuage the concerns of consumers. The Tobacco Control Act, passed in 2009, is Congress’ latest attempt to regulate the tobacco industry to ensure consumers are adequately informed about the health risks of tobacco products, including what tobacco manufactures can say about “modified risk tobacco products” such as e-cigarettes.
    [Show full text]
  • Case 3:18-Cv-02499-WHO Document 82 Filed 01/30/19 Page 1 of 118
    Case 3:18-cv-02499-WHO Document 82 Filed 01/30/19 Page 1 of 118 GUTRIDE SAFIER LLP Adam J. Gutride (State Bar No. 181446) 1 Seth A. Safier (State Bar No. 197427) Todd Kennedy (State Bar No. 250267) 2 Anthony Patek (State Bar No. 228964) 3 100 Pine Street, Suite 1250 San Francisco, California 94111 4 Telephone: (415) 639-9090 Facsimile: (415) 449-6469 5 [email protected] [email protected] 6 [email protected] 7 [email protected] 8 MIGLIACCIO & RATHOD LLP Nicholas Migliaccio, admitted pro hac vice 9 Jason Rathod, admitted pro hac vice 10 Esfand Nafisi (State Bar No. 320119) 388 Market Street, Suite 1300 11 San Francisco, CA 94111 Telephone: (202) 470-3520 12 Facsimile: (202) 800-2730 [email protected] 13 [email protected] 14 [email protected] 15 (additional counsel on signature page) Attorneys for Plaintiffs 16 17 UNITED STATES DISTRICT COURT 18 NORTHERN DISTRICT OF CALIFORNIA 19 SAN FRANCISCO DIVISION 20 IN RE: JUUL LABS, INC. PRODUCT CASE NO. 3:18-cv-2499 21 LITIGATION Honorable William H. Orrick 22 23 CONSOLIDATED AMENDED CLASS ACTION COMPLAINT 24 (CORRECTED) 25 26 JURY TRIAL DEMANDED 27 28 -1- Consolidated Amended Class Action Complaint Case 3:18-cv-02499-WHO Document 82 Filed 01/30/19 Page 2 of 118 TABLE OF CONTENTS 1 I. INTRODUCTION ..................................................................................................................... 5 2 II. PARTIES .................................................................................................................................
    [Show full text]
  • 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
    1 Peter A. Sandberg Ingaldson Fitzgerald, P.C. 2 813 W. Third Avenue Anchorage, Alaska 99501 3 (907) 258-8750 [email protected] 4 Robert J. Nelson 5 Lexi J. Hazam Sarah R. London 6 Fabrice N. Vincent (Pro Hac Vice anticipated) Reilly T. Stoler 7 LIEFF CABRASER HEIMANN & BERNSTEIN, LLP 275 Battery Street, 29th Floor 8 San Francisco, CA 94111-3339 Telephone: 415.956.1000 9 Facsimile: 415.956.1008 10 Wendy R. Fleishman Kartik S. Madiraju (Pro Hac Vice anticipated) 11 LIEFF CABRASER HEIMANN & BERNSTEIN, LLP 250 Hudson Street, 8th Floor 12 New York, NY 10013-1413 Telephone: 212.355.9500 13 Facsimile: 212.355.9592 14 Attorneys for Plaintiff 15 UNITED STATES DISTRICT COURT 16 FOR THE DISTRICT OF ALASKA 17 JOSEPH BURNS, by and through his Case No. 3:20-cv-00291-JWS PARENT and NATURAL GUARDIAN 18 MARGARET BURNS, COMPLAINT 19 Plaintiff, DEMAND FOR JURY TRIAL 20 v. 21 JUUL LABS, INC., previously d/b/a PAX Labs, Inc. and PLOOM Inc.; ALTRIA 22 Group, Inc.; Philip Morris USA, Inc.; Altria Client Services LLC; Altria Group 23 Distribution Company; Altria Enterprises LLC; Adam Bowen; James Monsees; 24 Nicholas Pritzker; Hoyoung Huh; Riaz Valani; Mother Murphy’s Labs, Inc.; 25 Alternative Ingredients, Inc.; Tobacco Technology, Inc.; eLiquitech, Inc.; ZIIP 26 Lab Co., Ltd.; and ZLAB, S.A., 27 Defendants. 28 Case 3:20-cv-00291-JWS Document 1 Filed 11/17/20 Page 1 of 125 1 TABLE OF CONTENTS 2 Page 3 I. INTRODUCTION .............................................................................................................. 1 II. JURISDICTION AND VENUE ......................................................................................... 8 4 III. THE PLAINTIFF ...............................................................................................................
    [Show full text]
  • Case 1:20-Cv-00896 Document 5 Filed 04/01/20 USDC Colorado Page 1 of 207
    Case 1:20-cv-00896 Document 5 Filed 04/01/20 USDC Colorado Page 1 of 207 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLORADO Civil Action No. CITY AND COUNTY OF DENVER, Plaintiff, v. JUUL LABS, INC. F/K/A PAX LABS, INC.; EONSMOKE LLC; ALTRIA GROUP, INC.; ALTRIA CLIENT SERVICES LLC; ALTRIA GROUP DISTRIBUTION COMPANY; NU MARK LLC; AND NU MARK INNOVATIONS, LTD.; Defendants. COMPLAINT Case 1:20-cv-00896 Document 5 Filed 04/01/20 USDC Colorado Page 2 of 207 TABLE OF CONTENTS I. INTRODUCTION ........................................................................................................ 1 II. JURISDICTION AND VENUE.................................................................................... 6 III. PARTIES ..................................................................................................................... 7 IV. ALLEGATIONS OF FACT........................................................................................ 10 A. JUUL: Runaway Commercial Success and Public Health Disaster .................. 10 1. Redesigning “the most successful consumer product of all time” ................................................................................................... 10 2. Following Big Tobacco’s footsteps: Nicotine Salts .............................. 16 JLI designed JUUL products to contain and deliver as much nicotine as possible .................................................................... 22 B. Following Big Tobacco’s Playbook, JLI Launched JUUL with a Blatantly Youth-Oriented Campaign
    [Show full text]
  • Complaint-SDUSD-V-JUUL.Pdf
    1 PANISH SHEA & BOYLE LLP Exempt from Filing Fees per BRIAN J. PANISH, State Bar No. 116060 Gov’t Code Section 6103 2 [email protected] RAHUL RAVIPUDI, State Bar No. 204519 3 [email protected] JESSE CREED, State Bar No. 272595 4 [email protected] 11111 Santa Monica Boulevard, Suite 700 5 Los Angeles, California 90025 Telephone: 310.477.1700 / Fax: 310.477.1699 6 BARON & BUDD, P.C. 7 John P. Fiske, State Bar No. 249256 [email protected] 8 Scott Summy (Pro Hac Vice) Texas Bar No. 19507500 9 [email protected] Jason J. Julius, State Bar No. 249036 10 [email protected] Victoria E. Sherlin, State Bar No. 312337 11 [email protected] 11440 West Bernardo Court Suite 265 12 San Diego, CA 92127 Telephone: 858.251.7424 / Fax: 214.520.1181 13 Attorneys for Plaintiff San Diego Unified School 14 District 15 SUPERIOR COURT OF THE STATE OF CALIFORNIA 16 COUNTY OF SAN DIEGO 17 SAN DIEGO UNIFIED SCHOOL DISTRICT, a ) Case No.: 18 unified school district organized and operating ) pursuant to the laws of the State of California; ) COMPLAINT FOR DAMAGES: 19 ) Plaintiff, ) 1. Public Nuisance 20 v. ) 2. Strict Liability – Design Defect ) 3. Strict Liability – Failure to Warn 21 JUUL LABS, INC., f/k/a PAX Labs, Inc. and ) 4. Negligence 22 PAX Labs Inc., ) ) DEMAND FOR A JURY TRIAL 23 Defendants. ) ) 24 ) 25 26 27 28 - 1 - COMPLAINT FOR DAMAGES 1 Plaintiff SAN DIEGO UNIFIED SCHOOL DISTRICT (“Plaintiff,” “SDUSD,” or “District”) 2 hereby brings the following complaint for damages against JUUL Labs, Inc., f/k/a PAX Labs, Inc.
    [Show full text]
  • Complaint (PDF)
    Case 2:18-cv-09605-JAK-PLA Document 1 Filed 11/14/18 Page 1 of 10 Page ID #:1 1 GIBSON, DUNN & CRUTCHER LLP AUSTIN V. SCHWING, SBN 211696 2 [email protected] 555 Mission Street, Suite 3000 3 San Francisco, CA 94105-0921 Telephone: 415.393.8200 4 Facsimile: 415.393.8306 5 GIBSON, DUNN & CRUTCHER LLP JESSICA R. CULPEPPER, SBN 304336 6 [email protected] 333 South Grand Avenue 7 Los Angeles, CA 90071-3197 Telephone: 213.229.7000 8 Facsimile: 213.229.7520 9 Attorneys for Defendant JUUL LABS, INC. 10 UNITED STATES DISTRICT COURT 11 CENTRAL DISTRICT OF CALIFORNIA 12 WESTERN DIVISION 13 14 TIMOTHY MALANEY; and CASE NO. 2:18-CV-09605 15 BRENDAN GORMAN, NOTICE OF REMOVAL OF CLASS 16 Plaintiffs, ACTION 17 v. (Los Angeles County Superior Court Case 18 JUUL LABS, INC.; and PAX LABS, No. 18STCV02948) INC., 19 Action Filed: October 26, 2018 Defendants. Trial Date: None Set 20 21 22 23 24 25 26 27 28 Gibson, Dunn & Crutcher LLP NOTICE OF REMOVAL OF CLASS ACTION Case 2:18-cv-09605-JAK-PLA Document 1 Filed 11/14/18 Page 2 of 10 Page ID #:2 1 TO THE CLERK OF THE UNITED STATES DISTRICT COURT FOR THE 2 CENTRAL DISTRICT OF CALIFORNIA, AND TO PLAINTIFFS TIMOTHY 3 MALANEY AND BRENDAN GORMAN AND THEIR COUNSEL OF 4 RECORD: 5 PLEASE TAKE NOTICE THAT, pursuant to the Class Action Fairness Act 6 of 2005, 28 U.S.C. §§ 1332, 1367, 1453, and 1711, Defendant JUUL Labs, Inc. 7 (“JUUL Labs” or “Defendant”) hereby removes the above-captioned action—with 8 reservation of all defenses and rights—from the Superior Court of the State of 9 California for the County of Los Angeles, Case No.
    [Show full text]
  • View / Open Final Thesis-Mcgonegal
    “CAN I RIP YOUR JUUL?” THE EVOLUTION OF THE ELECTRONIC CIGARETTE INDUSTRY, ITS PRODUCTS, AND MARKETING APPEALS by MATTHEW McGONEGAL A THESIS Presented to the School of Journalism and Communication and the Robert D. Clark Honors College in partial fulfillment of the requirements for the degree of Bachelor of Science November 2019 An Abstract of the Thesis of Matthew McGonegal for the degree of Bachelor of Science in the School of Journalism and Communication to be taken November 2019 Title: “Can I Rip Your JUUL?” The Evolution of the Electronic Cigarette Industry, its Products, and Marketing Appeals Approved: Autumn Shafer, Ph.D. Primary Thesis Advisor In recent years, public attitudes toward electronic cigarettes have undergone a fascinating transformation. What began as an underdeveloped, niche market for adult smokers looking to quit evolved into a hobbyist subculture as vaporizer technologies advanced and marketing appeals diverted from smoking cessation messages. Perceptions of the e-cigarette industry soon transformed again with the emergence of a new competitor: JUUL Labs. Since JUUL’s introduction to the market in 2015, it has grown to dominate the space in both market share and cultural relevance. Although e-cigarette makers have long promoted their products as a smoking cessation method, JUUL’s popularity with underage users has cast doubt over the public health benefits of e-cigarettes. This thesis explores the evolution of the e-cigarette industry’s products, marketing appeals, and audiences, as well as the product and marketing factors contributing to JUUL’s popularity with nicotine-naïve users. ii Acknowledgements First and foremost, I want to thank my primary thesis advisor, Assistant Professor Autumn Shafer, for her guidance and support through this strenuous but rewarding process.
    [Show full text]
  • Open PDF File, 1.5 MB, for JUUL Complaint
    COMMONWEALTH OF MASSACHUSETTS SUFFOLK, ss. SUPERIOR COURT DEPARTMENT OF THE TRIAL COURT RECEIVED FEB 1 2 2020 COMMONWEALTH OF MASSACHUSETTS Plaintiff, v. JUUL LABS, INC. and PAX LABS, INC., Civil Action No. Defendants. COMPLAINT 1. The Commonwealth of Massachusetts, by and through Attorney General Maura Healey, brings this action pursuant to the Massachusetts Consumer Protection Act, G.L. c. 93 A § 4. Defendants JUUL Labs, Inc. and its corporate predecessor, Pax Labs, Inc., (together, ;JUUL”) have engaged in unfair and deceptive acts and practices in violation of G.L. c. 93 A, § 2, and 940 C.M.R. 21.00 et seq. by willfully advertising and/or selling nicotine products to children, adolescents, and other consumers younger than the minimum legal sales age (“underage consumers”). JUUL’s misconduct has created a public health crisis and an epidemic of youth nicotine use and addiction, which constitutes a public nuisance for which JUUL is liable to the Commonwealth. 2. JUUL, more than any other company, bears responsibility for the fact that millions of young people nationwide are now addicted to e-cigarettes, reversing decades of progress in combatting underage tobacco and nicotine use and addiction. 1 3. JUUL has described itself as a “technology company,” but its chief technological innovation has been the creation of an e-cigarette that can deliver dramatically higher concentrations of a harmful, highly addictive chemical: nicotine. 4. Beginning with the advertising campaign that introduced the JUUL e-cigarette in 2015, JUUL has marketed its e-cigarette to consumers who cannot lawfully purchase the product. 5. JUUL explicitly identified its target audience as the “cool crowd,”a demographic of young people who were “fashionable, urban with a vibrant life,” and “enjoy[ed] going out to shows and events.” 6.
    [Show full text]